BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years

Jang, Eun Jung; Choe, Young June; Kim, Ryu Kyung; Park, Young-Joon

doi:10.1001/jamapediatrics.2022.5221

Cited by 16 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five of the NRSIs assessed vaccine effectiveness over time. 40 , 43 , 44 , 47 All reported a substantial reduction in vaccine effectiveness against SARS-CoV-2 infections of at least 15% from the timepoint of first measurement after two-dose vaccination to the timepoint of last measurement ( appendix 1 p 40 ). One study 32 reported vaccine effectiveness against omicron infections after the third dose (vaccine effectiveness 55% [50–60]) and reported no effect of waning protection up to 4 months after the booster.…”

Section: Resultsmentioning

confidence: 99%

Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis

Piechotta

Siemens

Thielemann

et al. 2023

The Lancet Child & Adolescent Health

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis

Piechotta

Siemens

Thielemann

et al. 2023

The Lancet Child & Adolescent Health

View full text Add to dashboard Cite

“…However, myocarditis after standard vaccination is rare in children aged 5–11 years (1 in 1 million doses) 35 ; it was not reported after 650,000 monovalent 36 or 950,000 bivalent booster 37 doses in this age group or in children aged 6 months to 5 years after one million standard vaccinations 38 . Recent studies evaluating the efficacy of wild‐type mRNA vaccines in children aged 5–11 years suggest a reduced protection against all omicron infections compared to previous variants, but protection against hospitalization and particularly severe COVID‐19 remained high 39–44 …”

Section: Discussionmentioning

confidence: 99%

“…38 Recent studies evaluating the efficacy of wild-type mRNA vaccines in children aged 5-11 years suggest a reduced protection against all omicron infections compared to previous variants, but protection against hospitalization and particularly severe COVID-19 remained high. [39][40][41][42][43][44] Our study has several limitations. designed the study and provided key resources.…”

Section: Effects Of Vaccination 14 Months After Wild-type Infection O...mentioning

confidence: 95%

Live‐virus neutralization of the omicron variant in children and adults 14 months after SARS‐CoV‐2 wild‐type infection

Stich

Benning

Speer

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Data on cross‐neutralization of the SARS‐CoV‐2 omicron variant more than 1 year after SARS‐CoV‐2 infection are urgently needed, especially in children, to predict the likelihood of reinfection and to guide vaccination strategies. In a prospective observational cohort study, we evaluated live‐virus neutralization of the SARS‐CoV‐2 omicron (BA.1) variant in children compared with adults 14 months after mild or asymptomatic wild‐type SARS‐CoV‐2 infection. We also evaluated immunity to reinfection conferred by previous infection plus COVID‐19 mRNA vaccination. We studied 36 adults and 34 children 14 months after acute SARS‐CoV‐2 infection. While 94% of unvaccinated adults (16/17) and children (32/34) neutralized the delta (B.1.617.2) variant, only 1/17 (5.9%) unvaccinated adults, 0/16 (0%) adolescents and 5/18 (27.8%) children <12 years of age had neutralizing activity against omicron (BA.1). In convalescent adults, one or two doses of mRNA vaccine increased delta and omicron neutralization 32‐fold, similar to a third mRNA vaccination in uninfected adults. Neutralization of omicron was 8‐fold lower than that of delta in both groups. In conclusion, our data indicate that humoral immunity induced by previous SARS‐CoV‐2 wild‐type infection more than 1 year ago is insufficient to neutralize the current immune escape omicron variant.

show abstract

“…We used data from the Korea COVID-19 Vaccine Effectiveness (K-COVE) cohort, a large-linked database combining all COVID-19 laboratory-confirmed cases and all COVID-19 immunization registry in South Korea. Detailed information about the K-COVE cohort has been published previously [11][12][13].…”

Section: Methodsmentioning

confidence: 99%

Comparative Effectiveness of BNT162b2 and NVX-CoV2373 Vaccines in Korean Adults

Park

Choe

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Various types of vaccines against SARS-CoV-2 have reduced the burden of coronavirus diseases 2019 (COVID-19) across the world. We conducted an observational study to evaluate the effectiveness of NVX-CoV2373 and BNT162b2 in providing protection in Korean adults. Methods: This study was a retrospective matched cohort study to emulate a target trial of three doses of NVX-CoV2373 (N-N-N) versus three doses of BNT162b2 (B-B-B) vaccines in presumed immune-naive adults. We used data from the Korea COVID-19 Vaccine Effectiveness (K-COVE) cohort, combining all COVID-19 laboratory-confirmed cases and all COVID-19 immunization registry, between February and November 2022. We calculated 40-week risk differences and risk ratios between the two vaccines. Results: A total of 3,019 recipients of NVX-CoV2373 vaccine and 3,027 recipients of BNT162b2 vaccine were eligible for the study. The 40-week risk ratios for recipients of the NVX-CoV2373 vaccine as compared with recipients of the BNT162b2 vaccine were 1.169 (95% CI, 1.015 to 1.347) for laboratory-confirmed SARS-CoV-2 infection, and 0.504 (95% CI, 0.126 to 2.014) for severe SARS-CoV-2 infection. Estimated risk of severe infection was 0.001 events per 1000 persons (95% CI, 0 to 0.003) for the NVX-CoV2373 vaccine and 0.002 events per 1000 persons (95% CI, 0.001 to 0.006) for BNT162b2 vaccine. Conclusion: This study identifies reduced risk of SARS-CoV-2 infection and severe infection after receipt of three doses of either NVX-CoV2373 or BNT162b2 vaccines in Korean adults. Direct, vaccine-conferred protection may be of importance among high risk persons to mitigate from serious clinical outcome from COVID-19.

show abstract

BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years

Abstract: This cohort study examines data for all children aged 5 to 11 years in South Korea to gauge the effectiveness of the BNT162b2 vaccine when the Omicron variant was the dominant SARS-CoV-2 infection in the country.

Cited by 16 publications

References 6 publications

Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis

Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis

Live‐virus neutralization of the omicron variant in children and adults 14 months after SARS‐CoV‐2 wild‐type infection

Comparative Effectiveness of BNT162b2 and NVX-CoV2373 Vaccines in Korean Adults

Contact Info

Product

Resources

About